Q2
LLY — Q2 2026 Financial Report Analysis
Eli Lilly's Q2 2026 revenue rose 48% to $22.97bn on 60% volume growth against a 13% decline in realized prices, but $2.8bn of acquired IPR&D charges from its 2026 acquisition spree held net income growth to 25%.